Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol.
Int J Obes Relat Metab Disord. 1998;22:227-229.
Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet.
Cancer Epidemiol Biomarkers Prev. 1994;3:591-595.
Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention.
J Cell Biochem Suppl. 1997;28-29:111-116.
Yuan F, Chen DZ, Liu K, et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer.
Anticancer Res. 1999;19:1673-1680.
Arnao MB, Sanchez-Bravo J, Acosta M. Indole-3-carbinol as a scavenger of free radicals.
Biochem Mol Biol Int. 1996;39:1125-1134.
Bradlow HL, Sepkovic DW, Telang NT, et al. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent.
Ann N Y Acad Sci. 1999;889:204-213.
Heaney RK, Fenwick GR. Natural toxins and protective factors in brassica species, including rapeseed.
Nat Toxins. 1995;3:233-237,242.
McDanell R, McLean AE, Hanley AB, et al. Chemical and biological properties of indole glucosinolates (glucobrassicins): a review.
Food Chem Toxicol. 1988;26:59-70.
Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention.
J Cell Biochem Suppl. 1997;28-29:111-116.
Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.
Gynecol Oncol. 2000;78:123-129.
Bradfield CA, Bjeldanes LF. Modification of carcinogen metabolism by indolylic autolysis products of
Brassica oleraceae.
Adv Exp Med Biol. 1991;289:153-163.
Bjeldanes LF, Kim JY, Grose KR, et al. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Proc Natl Acad Sci U S A. 1991;88:9543-9547.
Jellinck PH, Forkert PG, Riddick DS, et al. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation.
Biochem Pharmacol. 1993;45:1129-1136.
Arnao MB, Sanchez-Bravo J, Acosta M. Indole-3-carbinol as a scavenger of free radicals.
Biochem Mol Biol Int. 1996;39:1125-1134.
Kelloff GJ, Boone CW, Crowell JA, et al. New agents for cancer chemoprevention.
J Cell Biochem Suppl. 1996;26:1-28.
Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II].
Curr Med Chem. 1998;5:469-491.
Background information. Indole-3-carbinol (I3C). 700-06-1, June 28, 2000. National Institute of Environmental Health Sciences web site. Available at:
http://ntp-server.niehs.nih.gov/htdocs/Chem_Background/ExecS.../Indolecarbinoll. Accessed September 19, 2000.
Heaney RK, Fenwick GR. Natural toxins and protective factors in brassica species, including rapeseed.
Nat Toxins. 1995;3:233-237,242.
McDanell R, McLean AE, Hanley AB, et al. Chemical and biological properties of indole glucosinolates (glucobrassicins): a review.
Food Chem Toxicol. 1988;26:59-70.
Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.
Gynecol Oncol. 2000;78:123-129.
Rosen CA, Woodson GE, Thompson JW, et al. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis.
Otolaryngol Head Neck Surg. 1998;118:810-815.
Shertzer HG, Berger ML, Tabor MW. Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol.
Biochem Pharmacol. 1988;37:333-338.
Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.
Gynecol Oncol. 2000;78:123-129.
Background information. Indole-3-carbinol (I3C). 700-06-1, June 28, 2000. National Institute of Environmental Health Sciences web site. Available at:
http://ntp-server.niehs.nih.gov/htdocs/Chem_Background/ExecS.../Indolecarbinoll. Accessed September 19, 2000.
Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.
Gynecol Oncol. 2000;78:123-129.
Rosen CA, Woodson GE, Thompson JW, et al. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis.
Otolaryngol Head Neck Surg. 1998;118:810-815.
Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention.
J Cell Biochem Suppl. 1997;28-29:111-116.
Dashwood RH. Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables?
Chem Biol Interact. 1998;110:1-5.
Bailey GS, Hendricks JD, Shelton DW, et al. Enhancement of carcinogenesis by the natural anticarcinogen indole-3-carbinol.
J Natl Cancer Inst. 1987;78:931-934.
Meng Q, Yuan F, Goldberg ID, et al. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells.
J Nutr.
2000;130:2927-293l .
Chinni SR, Sarkar FH. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells.
Clin Cancer Res.
2002;8:1228-1236.
Hong C, Firestone GL, Bjeldanes LF. Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells.
Biochem Pharmacol.
2002;63:1085-1097.
Rahman KM, Sarkar FH. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells.
J Steroid Biochem Mol Biol.
2002;80:191-201.
Auborn KJ. Therapy for recurrent respiratory papillomatosis.
Antivir Ther.
2002;7:1-9.
Wilker C, Johnson L, Safe S. Effects of developmental exposure to indole-3-carbinol or 2,3,7,8-tetrachlorodibenzo-p-dioxin on reproductive potential of male rat offspring.
Toxicol Appl Pharmacol .
1996; 141:68-75.
Stoner G, Casto B, Ralston S, et al. Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol.
Carcinogenesis.
2002;23:265-272.
Naik R, Nixon S, Lopes A, et al. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia.
Int J Gynecol Cancer.
2006;16:786-90.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.